Larylin Husten-Stiller (Dropropizine)

Dropropizine acts on the central cough centre in the medulla, reducing the sensitivity of cough receptors to irritant stimuli. By modulating the neural pathways that trigger the cough reflex, it decreases cough frequency without producing significant sedation.

The exact dosage of Larylin Husten-Stiller is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of cough, and clinical judgment. Patients should follow the prescriber’s instructions and the product label.

Safety data for Dropropizine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Dropropizine is a centrally acting antitussive without opioid activity, offering cough relief with a lower risk of dependence compared with codeine‑based products. It is generally well tolerated, though its efficacy may be comparable to other non‑opioid agents such as dextromethorphan.

Larylin Husten-Stiller should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually as a tablet or liquid preparation, as directed by the prescriber. It should be swallowed with water and taken at the intervals recommended on the prescription label.

Serious but rare risks include allergic reactions such as rash, itching, swelling, or angioedema, and potential hepatic dysfunction. Patients should seek immediate medical attention if they experience signs of an allergic response or unexplained liver-related symptoms.

Individuals with known hypersensitivity to Dropropizine or any excipients in the formulation should avoid the product. Caution is also advised for patients with severe hepatic or renal impairment, and it should not be used in combination with other central antitussives without medical supervision.